-
公开(公告)号:US20240294497A1
公开(公告)日:2024-09-05
申请号:US18292743
申请日:2022-08-29
发明人: Mitsuo NAGAI , Takashi FUKUYAMA , Yasuaki KAMADA , Jun NIIJIMA , Hirofumi KURODA , Keiichi MURAKAMI , Yuki KAROJI , Hiroyuki SAITO , Masayuki OMORI , Yusuke MIYASHITA , Atsushi KAMADA , Masaaki MATSUDA , Takanori KODERA
IPC分类号: C07D401/14
CPC分类号: C07D401/14
摘要: Provided is compound (3d) or a salt thereof, wherein the content of compound (IM-7) is 0.48 mass % or lower.
-
公开(公告)号:USD1032850S1
公开(公告)日:2024-06-25
申请号:US29870316
申请日:2023-01-20
设计人: Rajeev Narayanan , David Levin , Alexander Scott
摘要: FIG. 1 is an isometric view of an embodiment of the health condition monitoring set;
FIG. 2 is a front view thereof;
FIG. 3 is a rear view thereof;
FIG. 4 is a top view thereof;
FIG. 5 is a bottom view thereof;
FIG. 6 is a right side view thereof; and,
FIG. 7 is a left side view thereof.-
公开(公告)号:US20240148895A1
公开(公告)日:2024-05-09
申请号:US18237663
申请日:2023-08-24
发明人: Masayuki MIYANO , Yuya NAKAZAWA , Kentaro ISO , Yuki YABE , Hirotatsu UMIHARA , Junichi TAGUCHI , Satoshi INOUE , Shuntaro TSUKAMOTO , Hiroyuki KOGAI , Atsumi YAMAGUCHI , Tsuyoshi AKAGI , Yohei MUKAI , Toshifumi HIRAYAMA , Masaki KATO , Toshiki MOCHIZUKI , Akihiko YAMAMOTO , Yuji YAMAMOTO , Takato SAKURADA
IPC分类号: A61K47/68
CPC分类号: A61K47/6889 , A61K47/6803 , A61K47/6849 , A61K47/6853 , A61K47/6855
摘要: An antibody-drug conjugate represented by formula (I):
(where
Ab is an antibody,
X is a group represented by formula (X-1), formula (X-2) or formula (X-3):
(where
at the left represents the binding site with NH and
at the right represents the binding side with D),
D is a group represented by formula (D-1) or formula (D-2):
(where
represents the binding site with X), and
n is in the range of about 1 to about 8).-
公开(公告)号:US11945807B2
公开(公告)日:2024-04-02
申请号:US17661909
申请日:2022-05-03
发明人: Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC分类号: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
CPC分类号: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/60 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K47/6871 , A61K47/6889 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/5011 , G01N33/574 , A61K2039/505 , A61K2039/53 , A61K2039/545 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , G01N2500/10
摘要: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
5.
公开(公告)号:US20240050462A1
公开(公告)日:2024-02-15
申请号:US17768283
申请日:2020-12-24
发明人: Seiji TAKEMOTO , Shuntaro ARASE , Yuta SUZUKI
IPC分类号: A61K31/713 , A61K9/107 , A61K9/127 , A61P13/02
CPC分类号: A61K31/713 , A61K9/107 , A61K9/1272 , A61P13/02
摘要: Disclosed is a pharmaceutical composition comprising a lipid complex, wherein the lipid complex comprises a double-stranded ribonucleic acid comprising a sense strand consisting of a nucleotide sequence set forth in SEQ ID NO: 145 and an antisense strand consisting of a nucleotide sequence set forth in SEQ ID NO: 146, and a pH of a solution of the lipid complex is 5.0 or less, or 7.5 or more.
-
公开(公告)号:US20240034777A1
公开(公告)日:2024-02-01
申请号:US18149905
申请日:2023-01-04
发明人: Malcolm Ian Roberts , James Martin Staddon , Hettihewage Alfred Rohan De Silva , Jared Spidel , Hirofumi Aoyagi , Shigeru Akasofu , Yutaka Hashizume , Kishan Agarwala
CPC分类号: C07K16/18 , C07K14/4711 , C12N15/85 , A61P25/28 , C12N15/62 , A61K39/3955 , C07K2317/24 , C12N2015/8518 , C07K2317/56 , C07K2317/34 , C07K2317/76 , C07K2317/565
摘要: Provided herein are antibodies that specifically bind Tau and methods of using the same.
-
公开(公告)号:US20230357386A1
公开(公告)日:2023-11-09
申请号:US18027413
申请日:2021-12-22
发明人: Tomomi KAWAKATSU , Akio YAMADA , Aki NAKATANI , Eiji INOUE
CPC分类号: C07K16/28 , C12N15/63 , C07K2317/565
摘要: Provided is an anti-EphA4 antibody capable of binding to EphA4 and enhancing the cleavage of EphA4, and a pharmaceutical composition comprising the antibody as an active ingredient. The anti-EphA4 antibody comprises a heavy chain comprising a heavy chain CDR1 of SEQ ID NO: 30; a heavy chain CDR2 of SEQ ID NO: 31; and a heavy chain CDR3 of SEQ ID NO: 32; and a light chain comprising a light chain CDR1 of SEQ ID NO: 33; a light chain CDR2 of SEQ ID NO: 34; and a light chain CDR3 of SEQ ID NO: 35, or a heavy chain comprising a heavy chain CDR1 of SEQ ID NO: 42; a heavy chain CDR2 of SEQ ID NO: 31; and a heavy chain CDR3 of SEQ ID NO: 43; and a light chain comprising a light chain CDR1 of SEQ ID NO: 44; a light chain CDR2 of SEQ ID NO: 34; and a light chain CDR3 of SEQ ID NO: 35.
-
公开(公告)号:US11725015B2
公开(公告)日:2023-08-15
申请号:US17167480
申请日:2021-02-04
发明人: Yoshito Kishi , Kazunobu Kira , Ken Ito
IPC分类号: C07D493/22 , A61P35/00 , A61K31/357 , A61K39/395 , C07K16/28 , A61K39/00
CPC分类号: C07D493/22 , A61K31/357 , A61K39/3955 , A61P35/00 , C07K16/2818 , C07K16/2863 , A61K2039/505 , A61K2300/00
摘要: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.
-
公开(公告)号:US20230250182A1
公开(公告)日:2023-08-10
申请号:US18009109
申请日:2021-06-21
IPC分类号: C07K16/28 , A61K31/47 , A61K31/277 , A61P35/00
CPC分类号: C07K16/2896 , A61K31/47 , A61K31/277 , A61P35/00 , A61K2039/545
摘要: Provided herein are methods of treating cancer (e.g., RCC) or von-Hippel Lindau disease, which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) a HIF-2α inhibitor; and (c) lenvatinib, or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.
-
公开(公告)号:US20230172924A1
公开(公告)日:2023-06-08
申请号:US18008304
申请日:2021-07-29
发明人: Satoshi KAWANO , Saori Miyano , Kyoko NISHIBATA , Sayo FUKUSHIMA
IPC分类号: A61K31/4545 , A61K31/565 , A61K31/4196 , A61K31/566 , A61P35/00
CPC分类号: A61K31/4545 , A61K31/565 , A61K31/4196 , A61K31/566 , A61P35/00
摘要: Disclosed is a therapeutic agent for breast cancer, said therapeutic agent comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof that is to be administered in combination with an estrogen receptor antagonist or an aromatase inhibitor.
-
-
-
-
-
-
-
-
-